Skip To Main Content
James Sterling on Muck Rack

James Sterling

As seen in: Medium, Scribd, Kotaku, Taylor & Francis Online, Destructoid, BioRxiv, Cell Press, Loudoun Times-Mirror, Embedded, Jimquisition and

Get in touch with James

Contact James, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Dual and Triple Agonists Explained: GLP-1, GIP and Glucagon

|
By James Sterling, Louise Howard
| lifesciencedaily.news
Obesity and diabetes medicine has moved a long way from the single-hormone era. Dual and triple agonists are engineered molecules that switch on two or three hormone receptors at once. They now dominate the late-stage pipeline, and the highest doses tested have produced mean weight reductions approaching 30 per cent in randomised trials. Making sense of them means understanding three hormones: GLP-1, GIP and glucagon.
Open in Who Shared Issue with article?

Ziltivekimab ZEUS Trial: What the Null Result Means

|
By James Sterling, Louise Howard
| lifesciencedaily.news
The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation exactly as intended across more than 6,300 high-risk patients. It produced no reduction in the composite of cardiovascular death, non-fatal heart attack and non-fatal stroke.
Open in Who Shared Issue with article?

Singapore Radiopharmaceutical Market: How H2 2026 Looks

|
By James Sterling, Louise Howard
| lifesciencedaily.news
The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point.
Open in Who Shared Issue with article?
See all 384 articles